|Table of Contents|

Adjuvant compound yew capsules in maintenance treatment for advanced non-small cell lung cancer with qi deficiency and phlegm stasis syndrome:A multicenter,large sample,prospective cohort study

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 09
Page:
1631-1637
Research Field:
Publishing date:

Info

Title:
Adjuvant compound yew capsules in maintenance treatment for advanced non-small cell lung cancer with qi deficiency and phlegm stasis syndrome:A multicenter,large sample,prospective cohort study
Author(s):
WANG Xueqian1; ZHANG Ying1; DONG Jun1; WANG Wei2; JIAO Zhimin3; ZHANG Yong4; JIANG Yilan5; YANG Zuyi6; XUE Wenhan7; WANG Huijuan8; DU Zhenli9; WANG Xinjie10; LI Runpu11; SUN Hongmei12; CAO Xiaohong13; ZHANG Meiying1; HOU Wei1
Keywords:
adjuvant compound yew capsules; non-small cell lung cancer; maintenance treatment; progression-free survival time; quality of life; cohort study
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2024.09.010
Abstract:
Objective:To investigate the clinical efficacy and safety of adjuvant compound yew capsules for maintenance treatment of advanced non-small cell lung cancer (NSCLC) with Qi deficiency and phlegm stasis syndrome.Methods:Through a multicenter,large sample,prospective cohort study,the patients with stable disease and above into maintenance treatment after 4~6 cycles of first-line chemotherapy were included.And they were divided into the treatment group (160 cases) and the control group (109 cases) according to their willingness.The control group was given single drug of gemcitabine and pemetrexed for squamous cell carcinoma and non-squamous cell carcinoma respectively,and the treatment group was given adjuvant compound yew capsules for maintenance treatment.Both groups were given 21 days as 1 course of treatment,with at least 2 courses intervened,with quality of life evaluated every cycle and imaging efficacy evaluated every 2 courses of treatment.Progression-free survival time (PFS) and quality of life were compared between the two groups,and drug safety evaluation was also performed.Results:Among the 269 enrolled patients,246 patients had PFS endpoint events (91.45%),including 145 patients in the treatment group with a median PFS of 106 days and 101 patients in the control group with a median PFS of 120 days,with no statistical significance between the two groups in PFS (P＞0.05).The American lung cancer quality of life scale (FACT-L4.0) and the EuroQol five dimension scale (EQ-5D-VAS) were used to compare the scores of life quality of the two groups.Both of the two life quality assessment scales suggested that the treatment group had an advantage over the control group in improving the quality of life (P＜0.05).During the treatment,a total of 19 patients in both groups developed ADR,including 7 patients in the treatment group (4.38%) and 12 patients in the control group (11.01%).The incidence of ADR was lower in the treatment group，especially manifested in adverse reactions of bone marrow suppression.Conclusion:In terms of prolonging PFS,the efficacy of adjuvant compound yew capsules in the maintenance treatment of advanced NSCLC with Qi deficiency and phlegm stasis is not inferior to that of single drug maintenance chemotherapy in modern medicine,and adjuvant compound yew capsules has more advantages in terms of high quality of life and low adverse reactions.

References:

［1］ZHENG RS,ZHANG SW,ZENG HM,et al.Cancer incidence and mortality in China,2016［J］.JNCC,2022,2(1):1-9.
［2］SCAGLIOTTI GV,MARINIS FD,RINALDI M,et al.Phase Ⅲ randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer［J］.J Clin Oncol,2002,20(21):4285-4291.
［3］GOVINDAN R,PAGE N,MORGENSZTERN D,et al.Changing epidemiology of small-cell lung cancer in the United States over the last 30 years:analysis of the surveillance,epidemiologic,and end results database［J］.J Clin Oncol,2006,24:4539-4544.
［4］SCHILLER JH,HARRINGTON D,BELANI CP,et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer［J］.N Engl J Med,2002,346(2):92-98.
［5］FOSSELLA F,PEREIRA JR,VON PAWEL J,et al.Randomized,multinational,phase Ⅲ study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer:the TAX 326 study group［J］.J Clin Oncol,2003,21(16):3016-3024.
［6］SUN JM,PARK JO,WON YW,et al.Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer?Implications for selection of patients for maintenance therapy［J］.J Thorac Oncol,2010,5（4）:540-545.
［7］GERBER DE,RASCO DW,LE P,et al.Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States:real-world considerations for maintenance therapy［J］.Journal of Thoracic Oncology,2011,6(2):365-371.
［8］STINCHCOMBE TE,SOCINSKI MA.Treatment paradigms for advanced stage non-smallcell lung cancer in the era of multiple lines of therapy［J］.J Thorac Oncol,2009,4(2):243-250.
［9］LEE JE,CHUNG CU.Update on the evidence regarding maintenance therapy［J］.Tuberc Respir Dis,2014,76(1):1-7.
［10］NOVELLO S,BARLESI F,CALIFANO R,et al.Metastatic non-small-cell lung cancer:ESMO clinical practice guidelines for diagnosis,treatment and follow-up［J］.Ann Oncol,2016,27(suppl 5):v1-v27.
［11］HANNA N,JOHNSON D,TEMIN S,et al.Systemic therapy for stage Ⅳ non-small-cell lung cancer:American society of clinical oncology clinical practice guideline update［J］.J Clin Oncol,2017,35(30):3484-3515.
［12］MCMULLEN S,HESS LM,KIM ES,et al.Treatment decisions for advanced non-squamous non-small cell lung cancer:patient and physician perspectives on maintenance therapy［J］.Patient,2019,12(2):223-233.
［13］王学谦,侯炜,郑佳彬,等.中医综合治疗方案维持治疗晚期非小细胞肺癌的多中心、大样本、前瞻性队列研究［J］.中医杂志,2020,61(08):690-694. WANG XQ，HOU W，ZHENG JB，et al.Comprehensive traditional chinese medicine therapeutic scheme in maintenance treatment for advanced non-small cell lung cancer:a multicenter，large-sample and prospective cohort study［J］.Journal of Traditional Chinese Medicine,2020,61(08):690-694.
［14］蔡华荣,张海梅.复方红豆杉胶囊用于非小细胞肺癌术后转移患者维持治疗效果观察［J］.现代中西医结合杂志,2019,28(15):1618-1621,1651. CAI HR,ZHANG HM.Observation on the effect of compound Chinese yew capsule in the maintenance of patients with non-small cell lung cancer after postoperative metastasis［J］.Modern Journal of Integrated Traditional Chinese and Western Medicine,2019,28(15):1618-1621,1651.
［15］肖锡岗.复方红豆杉胶囊治疗三阴乳腺癌41例［J］.中国中医药现代远程教育,2017,15(05):96-97. XIAO XG.Compound hongdoushan capsule in treating triple-negative breast cancer for 41 cases［J］.Chinese Medicine Modern Distance Education of China,2017,15(05):96-97.
［16］邹胜泽.复方红豆杉胶囊联合脂质体阿霉素治疗卵巢癌复发临床研究［J］.新中医,2019,51(08):179-182. ZOU SZ.Clinical study on the combination of compound taxus capsules and liposome adriamycin in the treatment of recurrent ovarian cancer［J］.Journal of New Chinese Medicine,2019,51(08):179-182.
［17］杨远游，程海明，宁健，等.伽马刀联合复方红豆杉胶囊治疗高龄晚期非小细胞肺癌疗效分析［J］.现代肿瘤医学，2015，23（17）：2433-2436. YANG YY,CHENG HM,NING J,et al.The effectiveness of Gama-knife combined with Hongdoushan capsules in the treatment of elderly patients with advanced non-small cell lung cancer［J］.Modern Oncology，2015，23（17）：2433-2436.
［18］张晓炜.复方红豆杉胶囊联合TP方案治疗中晚期非小细胞肺癌的疗效观察［J］.陕西中医,2015,36(07):833-835. ZHANG XW.Observation on the therapeutic effect of compound yew capsule combined with TP regimen in the treatment of advanced non-small cell lung cancer［J］.Shaanxi Journal of Traditional Chinese Medicine,2015,36(07):833-835.
［19］贺兼斌,廖慧中.复方红豆杉胶囊对老年Ⅲ、Ⅳ期非小细胞肺癌患者的治疗作用［J］.临床医学,2012,32(11):53-55. HE JB,LIAO HZ.The therapeutic effect of compound yew capsule on elderly patients with stage Ⅲ and Ⅳ non-small cell lung cancer［J］.Clinical Medicine,2012,32(11):53-55.
［20］中华人民共和国卫生部.原发性肺癌诊疗规范(2011年版) ［S］.北京:中国标准出版社，2011:2. Ministry of Health of the People’s Republic of China.Diagnosis and Treatment Standards for Primary Lung Cancer (2011 Edition)［S］.Beijing:China Standards Publishing House,2011:2.
［21］ETTINGER DS,WOOD DE,AISNER DL,et al.Non-small cell lung cancer,version 5.2017,NCCN clinical practice guidelines in oncology［Z］.J Natl Compr Canc Netw,2017,15:504-535.
［22］林洪生.恶性肿瘤中医诊疗指南［M］.北京:人民卫生出版社，2014:242-267. LIN HS.Guidelines of diagnosis and therapy in oncology with traditional Chinese medicine［M］.Beijing:People’s Health Publishing House,2014:242-267.
［23］HAN Y，WANG H，XU W，et al.Chinese herbal medicine as maintenance therapy for improving the quality of life for advanced non-small cell lung cancer patients［J］.Complement Ther Med，2016，24(2):81-89.
［24］董志毅,王丽新.中国版EQ-5D效用值评价体系对局部晚期及晚期肺癌患者生活质量评估的价值［J］.同济大学学报(医学版),2018,39(05):83-87. DONG ZY,WANG LX.Quality of life in patients with locally advanced of advanced lung cancer evaluated by EQ-5D Chinese-TTO［J］.Journal of Tongji University(medical science),2018,39(05):83-87.
［25］李博,高蕊,李睿,等.药物临床试验不良反应/不良事件关联性判定方法研究探讨［J］.中国新药杂志,2014,23(12):1465-1470. LI B,GAO R,LI R,et al.Causal determ ination of the adverse events and adverse drug reactions in drug clinical trials［J］.Chinese Journal of New Drugs,2014,23(12):1465-1470.
［26］BRODOWICZ T,KRZAKOWSKI M,ZWITTER M,et al.Cisplatin andgemcitabine first-line chemotherapy followed by maintenance gemcitabine or bestsupportive care in advanced non-small cell lung cancer:a phase Ⅲ trial［J］.Lung Cancer,2006,52(2):155-163.
［27］PROL M，CHOUAID C，PROL D，et al.Randomized，phase Ⅲ study of gemcitabine or erlotinib maintenance therapy versus observation，withpredefined second-line treatment，after cisplatin- gemcitabine inductionchemotherapy in advanced non-small-cell lung cancer［J］.J Clin Oncol，2012，30(28):3516-3524.
［28］PAZ-ARES LG,DE MARINIS F,DEDIU M,et al.PARAMOUNT:Final overall survival results of the phase Ⅲ study of maintenance pemetrexed versus placebo immediately afterinduction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer［J］.J Clin Oncol,2013,31(23):2895-2902.
［29］CIULEANU T，BRODOWICZ T，ZIELINSKI C，et al.Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer:a randomised，double- blind，phase 3 study［J］.Lancet，2009，374(9699):1432-1440.
［30］BELANI CP,BRODOWICZ T,CIULEANU TE,et al.Quality of life in patients with advanced non-small-cell lungcancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN):results from a randomised,double-blind,phase 3 study［J］.Lancet Oncol,2012，13(3):292-299.
［31］WANG X,LIN H,LIYUAN LV,et al.A meta-analysis of Kang`ai injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer［J］.J Cancer Res Ther,2015,11(3):558-564.
［32］LIU J，LIN HS，HOU W，et al.Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer:a multicenter，prospective，cohort study［J］.Chin J Integr Med，2017，23(10):733-739.
［33］王学谦,侯炜,董海涛,等.芪珍胶囊与化疗联合治疗恶性肿瘤的多中心随机对照临床研究［J］.中华中医药杂志,2015,30(06):1968-1971. WANG XQ,HOU W,DONG HT,et al.Multi-center randomized controlled clinical study of treating malignant tumor with qizhen capsule combined with chemotherapy［J］.China Journal of Chinese Materia Medica,2015,30(06):1968-1971.
［34］刘强,王沈玉,梁秋,等.消岩汤联合维持治疗在晚期非小细胞肺癌中的效果及安全性［J］.当代医学,2022,28(11):100-102. LIU Q,WANG SY,LIANG Q,et al.Effect and safety of Xiaoyan decoction combined with maintenance therapy in advanced non-small cell lung cancer［J］.Contemporary Medicine,2022,28(11):100-102.
［35］孔维嘉,丁彤晶,王玥,等.王笑民治肾解毒法维持治疗晚期非小细胞肺癌经验［J］.河北中医,2022,44(11):1773-1777. KONG WJ,DING TJ,WANG Y,et al.Wang Xiaomin’s experience in maintaining the treatment of advanced non-small cell lung cancer with kidney detoxification therapy［J］.Hebei J TCM，2022,44(11):1773-1777.
［36］张静.植物红豆杉的抗癌药用价值研究［J］.中国药业,2014,23(01):1-3. ZHANG J.Medicinal value of anti-cancer plant taxus chinensis［J］.China Pharmaceuticals,2014,23(01):1-3.
［37］TAKESHITA N,ENOKIDA T,OKANO S,et al.Weekly paclitaxel,carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck(R/M SCCHN)［J］.Oral Oncol,2023,147:106615.
［38］陈光亮,张磊,陈平,等.复方药物研发的现状与展望［J］.中国新药杂志,2016,25(19):2205-2210. CHEN GL,ZHANG L,CHEN P,et al.The status and prospect of research and development of drug combinations［J］.Chinese Journal of New Drugs,2016,25(19):2205-2210.
［39］KANG KA,YAO CW,PIAO MJ,et al.Anticolon cancer effect of korean red ginseng via autophagy- and apoptosis-mediated cell death［J］.Nutrients,2022,14(17):3558.
［40］ZHANG Z,YUNG KK,KO JK.Therapeutic intervention in cancer by isoliquiritigenin from licorice:a natural antioxidant and redox regulator［J］.Antioxidants (Basel),2022，11(7):1349.
［41］董军.复方红豆杉胶囊维持治疗晚期非小细胞肺癌疗效及其机制研究［D］.北京:中国中医科学院,2023. DONG J.Study on the efficacy and mechanism of compound taxus capsules in the maintenance treatment of advanced non small cell lung cancer［D］.Beijing:China Academy of Chinese Medical Sciences,2023.
［42］蒋宁.复方红豆杉胶囊对中晚期肺鳞癌（气虚痰瘀证）维持治疗无进展生存期的临床观察［D］.甘肃:甘肃中医药大学,2020. JANG N.Clinical observation on the progressive survival period of compound taxus capsules in the maintenance treatment of middle and late stage lung squamous cell cancer (qi deficiency and phlegm stasis syndrome)［D］.Gansu:Gansu University of Traditional Chinese Medicine,2020.
［43］楚亚楠.复方红豆杉胶囊维持治疗Ⅲ/Ⅳ期肺腺癌（气虚痰瘀证）的临床疗效观察［D］.甘肃:甘肃中医药大学,2020. CHU YN.Clinical observation on the maintenance treatment of stage Ⅲ/Ⅳ pulmonary adenocarcinoma(qi deficiency and phlegm stasis syndrome) with compound taxus capsules［D］.Gansu:Gansu University of Traditional Chinese Medicine,2020.
［44］李丛煌,刘瑞,郑红刚,等.晚期非小细胞肺癌中医证候分布及动态演变临床研究［J］.中医学报,2015,30(08):1085-1088. LI CH,LIU R,ZHENG HG,et al.Clinical study of the distribution and dynamic evolution of traditional chinese medicine syndromes for advanced non-small-cell lung cancer［J］.China Journal of Chinese Medicine,2015,30(08):1085-1088.
［45］何菊,杨涛,戴彩艳,等.基于复杂网络分析名老中医治疗肺癌的核心病机及用药规律［J］.世界科学技术-中医药现代化,2021,23(05):1478-1483. HE J,YANG T,DAI CY,et al.Analysis of the core pathogenesis and medication rules in the prominent tcm doctors’treatment of lung cancer based on the complex network［J］.Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology,2021,23(05):1478-1483.

Memo

Memo:
National Natural Science Foundation of China（No.C12021A01801）;中国中医科学院科技创新工程重大攻关项目（编号：C12021A01801）；国家中医药管理局中医药创新团队及人才支持计划项目（编号：ZYYCXTD-C-202205）；“优秀青年科技人才(创新类)”培养专项(编号：ZZ14-YQ-013)；北京市科学技术协会-青年人才托举工程(编号:BYESS2023357)
Last Update: 2024-03-29